Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Postibrutinib outcomes in patients with mantle cell lymphoma

Blood (2016) 127 (12): 1559–1563.

https://doi.org/10.1182/blood-2015-10-673145

Published: 2016

Journal Articles

Final Results of a Phase 1-2 Study of Vorinostat (SAHA), Cladribine, and Rituximab (SCR) Relapsed B-Cell Non-Hodgkin’s Lymphoma and Previously Untreated Mantle Cell Lymphoma

Stephen Spurgeon, MD, Kamal Sharma, DO, David F. Claxton, MD, Christopher Ehmann, MD, Sara Shimko, BS, August Stewart, Samir Parekh, MD, Violetta V. Leshchenko, PhD, Yiyi Chen, PhD, Motomi Mori, Jeffrey J. Pu, MD PhD, Elliot Epner, MD PhD

Blood (2014) 124 (21): 1714.

https://doi.org/10.1182/blood.V124.21.1714.1714

Published: 2014

Journal Articles

Consolidative Autologous Stem Cell Transplant for Double Hit Lymphoma

Andy I Chen, MDPhD, Craig Okada, MD PhD, Nate Gay, MD, Phil Reiss, MD, Stephen Spurgeon, MD, Guang Fan, MD PhD, Rita M. Braziel, MD, Richard T. Maziarz, MD

Blood (2014) 124 (21): 3993.

https://doi.org/10.1182/blood.V124.21.3993.3993

Published: 2014

Journal Articles

Clinical Activity Of Idelalisib (GS-1101), a Selective Inhibitor Of PI3Kδ, In Phase 1 and 2 Trials In Chronic Lymphocytic Leukemia (CLL): Effect Of Del(17p)/TP53 Mutation, Del(11q), IGHV Mutation, and NOTCH1 Mutation

Blood (2013) 122 (21): 1632.

https://doi.org/10.1182/blood.V122.21.1632.1632

Published: 2013

Journal Articles

Phase 1 Study of TRU-016, An Anti-CD37 SMIP™ Protein in Relapsed and/or Refractory NHL Patients

John M. Pagel, MD, PhD, Stephen Spurgeon, MD, Farrukh Awan, MD, MS, Kristie A. Blum, MD, Mark C Lanasa, MD, PhD, Ian W. Flinn, MD, PhD, Scott Stromatt, MD, John C. Byrd, MD, Ajay K. Gopal, MD

Blood (2011) 118 (21): 1636.

https://doi.org/10.1182/blood.V118.21.1636.1636

Published: 2011

Journal Articles

Phase 1 Study of Tru-016, An Anti-CD37 SMIP™ Protein in Naïve and Relapsed and/or Refractory CLL Patients

Farrukh T Awan, MD, MS, John M. Pagel, MD, PhD, Leslie A Andritsos, MD, Ajay K. Gopal, MD, Richard R. Furman, MD, Stephen Spurgeon, MD, Delva Deauna-Limayo, MD, Scott Stromatt, MD, John C. Byrd, MD

Blood (2011) 118 (21): 1792.

https://doi.org/10.1182/blood.V118.21.1792.1792

Published: 2011

Journal Articles

CX-4945, An Orally Bioavailable Selective Inhibitor of Casein Kinase 2 (CK2), Exhibits Anti-Tumor Activity in Hematologic Malignancies,

Renee C Prins, M.D., Stephen Spurgeon, MD, Jeffrey W Tyner, PhD, Luke B Fletcher, Abdusebur Jemal, Jade A Bryant, BS, Russell T Burke, Bill H Chang, MD, PhD, Tibor Kovacsovics, MD, Brian J. Druker, Marc M Loriaux, MD, PhD

Blood (2011) 118 (21): 3512.

https://doi.org/10.1182/blood.V118.21.3512.3512

Published: 2011

Journal Articles

A Phase I/II Study of Vorinostat (SAHA), Cladribine (2-CdA), and Rituximab Shows Significant Activity in Previously Untreated Mantle Cell Lymphoma

Stephen Spurgeon, MD, Andy I Chen, MD, PhD, Craig Okada, MD, PhD, Samir Parekh, MD, Violetta V. Leshchenko, PhD, Gundula Palmbach, Bashi Ratterree, RN, Nan Subbiah, Christine Capper, RN, Elliot M Epner, MD, PhD

Blood (2011) 118 (21): 441.

https://doi.org/10.1182/blood.V118.21.441.441

Published: 2011

Journal Articles

Cladribine Plus Rituximab Is An Effective Therapy for Newly Diagnosed Mantle Cell Lymphoma

Stephen Spurgeon, MD, Talia Pindyck, MD, Marc M Loriaux, MD, PhD, Craig Okada, MD, PhD, Kamal Abbi, Yiyi Chen, Zunqui Chen, Elana Mater, Elliott Epner, MD, PhD

Blood (2010) 116 (21): 4910.

https://doi.org/10.1182/blood.V116.21.4910.4910

Published: 2010

Journal Articles

Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Brad Kahl, MD, John C. Byrd, MD, Ian W. Flinn, MD, PhD, Nina Wagner-Johnston, MD, Stephen Spurgeon, MD, Don M Benson, Jr, MD, Richard R. Furman, MD, Jennifer R Brown, MD, PhD, Steven Coutre, MD, Brian Lannutti, PhD, Neil A. Giese, Ph.D., Roger G Ulrich, Ph.D., Heather K Webb, Ph.D., Sissy Peterman, Leanne Holes, Albert S Yu, MD

Blood (2010) 116 (21): 1777.

https://doi.org/10.1182/blood.V116.21.1777.1777

Published: 2010

Journal Articles

A Highly Selective AKT 1/2 Inhibitor Abrogates AKT Signaling and Is Cytotoxic to Primary Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Cells

Luke B Fletcher, Stephen Spurgeon, MD, Jeffrey W Tyner, PhD, Brian J Druker, MD, Marc M Loriaux, MD, PhD

Blood (2010) 116 (21): 3594.

https://doi.org/10.1182/blood.V116.21.3594.3594

Published: 2010

Journal Articles

Forodesine, a Purine Nucleoside Phosphorylase (PNP) Inhibitor, Shows Clinical Activity In a Phase 2 Trial In Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL) – Interim Analysis

Taimur Sher, MD, Jose Azar, MD, Stephen Spurgeon, MD, John Catalano, MBBS, FRACP, FRCPA, Richard R. Furman, MD, Miles Prince, MD, FRACP, FRCPA, Nancy L. Bartlett, MD, Simon Durrant, MBBS, FRCP, FRCPath, Ralph Boccia, MD, Aisha Masood, MD, Scott Lyman, MS, Jean Cantey-Kiser, William P Sheridan, MB, BS, Asher Chanan-Khan, MD

Blood (2010) 116 (21): 1397.

https://doi.org/10.1182/blood.V116.21.1397.1397

Published: 2010

Journal Articles

P505-15, a Highly Selective SYK Inhibitor, Shows Significant Activity In Primary CLL Cells and Is Synergistic with Fludarabine at Low Concentrations

Stephen Spurgeon, MD, Luke B Fletcher, Jeffrey W Tyner, PhD, Brian J Druker, MD, Anjali Pandey, PhD, Uma Sinha, PhD, Marc M Loriaux, MD, PhD

Blood (2010) 116 (21): 2839.

https://doi.org/10.1182/blood.V116.21.2839.2839

Published: 2010

Journal Articles

A Small-Molecule Inhibitor Screen Rapidly Identifies Therapeutic Targets and Individualized Therapeutic Strategies In Patients with Acute and Chronic Leukemias

Jeffrey W Tyner, PhD, Stephen Spurgeon, MD, Luke B Fletcher, Wayne Yang, Tibor Kovacsovics, MD, Brian J Druker, MD, Marc M Loriaux, MD, PhD

Blood (2010) 116 (21): 2754.

https://doi.org/10.1182/blood.V116.21.2754.2754

Published: 2010

Journal Articles

Evaluation of CPX-351 (cytarabine:daunorubicin) Liposome Injection Anti-Leukemic Activity Against Primary Patient Leukemia Cells

Jeffrey W Tyner, PhD, Paul Tardi, PhD, Lawrence Mayer, PhD, Luke B Fletcher, Stephen Spurgeon, MD, Tibor Kovacsovics, MD, Marc M Loriaux, MD, PhD

Blood (2010) 116 (21): 2886.

https://doi.org/10.1182/blood.V116.21.2886.2886

Published: 2010

NARROW

Postibrutinib outcomes in patients with mantle cell lymphoma

Final Results of a Phase 1-2 Study of Vorinostat (SAHA), Cladribine, and Rituximab (SCR) Relapsed B-Cell Non-Hodgkin’s Lymphoma and Previously Untreated Mantle Cell Lymphoma

Consolidative Autologous Stem Cell Transplant for Double Hit Lymphoma

Clinical Activity Of Idelalisib (GS-1101), a Selective Inhibitor Of PI3Kδ, In Phase 1 and 2 Trials In Chronic Lymphocytic Leukemia (CLL): Effect Of Del(17p)/TP53 Mutation, Del(11q), IGHV Mutation, and NOTCH1 Mutation

Phase 1 Study of TRU-016, An Anti-CD37 SMIP™ Protein in Relapsed and/or Refractory NHL Patients

Phase 1 Study of Tru-016, An Anti-CD37 SMIP™ Protein in Naïve and Relapsed and/or Refractory CLL Patients

CX-4945, An Orally Bioavailable Selective Inhibitor of Casein Kinase 2 (CK2), Exhibits Anti-Tumor Activity in Hematologic Malignancies,

A Phase I/II Study of Vorinostat (SAHA), Cladribine (2-CdA), and Rituximab Shows Significant Activity in Previously Untreated Mantle Cell Lymphoma

Cladribine Plus Rituximab Is An Effective Therapy for Newly Diagnosed Mantle Cell Lymphoma

Clinical Safety and Activity In a Phase 1 Study of CAL-101, An Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, In Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

A Highly Selective AKT 1/2 Inhibitor Abrogates AKT Signaling and Is Cytotoxic to Primary Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Cells

Forodesine, a Purine Nucleoside Phosphorylase (PNP) Inhibitor, Shows Clinical Activity In a Phase 2 Trial In Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL) – Interim Analysis

P505-15, a Highly Selective SYK Inhibitor, Shows Significant Activity In Primary CLL Cells and Is Synergistic with Fludarabine at Low Concentrations

A Small-Molecule Inhibitor Screen Rapidly Identifies Therapeutic Targets and Individualized Therapeutic Strategies In Patients with Acute and Chronic Leukemias

Evaluation of CPX-351 (cytarabine:daunorubicin) Liposome Injection Anti-Leukemic Activity Against Primary Patient Leukemia Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only